Skip to main content
Top
Published in: BMC Infectious Diseases 1/2010

Open Access 01-12-2010 | Research article

Factors associated with mortality in patients with tuberculosis

Authors: David J Horne, Rebecca Hubbard, Masahiro Narita, Alexia Exarchos, David R Park, Christopher H Goss

Published in: BMC Infectious Diseases | Issue 1/2010

Login to get access

Abstract

Background

Known risk factors for death following a diagnosis of tuberculosis may not be applicable to current U.S. cases. We evaluated the factors associated with all-cause mortality in patients with tuberculosis in Washington State.

Methods

Using data from the Tuberculosis Information Management System of Washington State, we conducted a cohort study of all residents diagnosed with tuberculosis from 1993 through 2005. Death from any cause was ascertained through the Washington State Death Certificate Data Files. Proportional hazards models were used to estimate the independent effect on all-cause mortality of demographic, clinical, and behavioral characteristics.

Results

During a median follow-up of 6 years in 3451 patients treated for tuberculosis, there were 417 deaths. Mortality was independently associated with increasing age, male gender, HIV-coinfection, and U.S. birth. Within 1 year of tuberculosis diagnosis, treatment by a private provider and the use of directly observed therapy were also independently associated with increased mortality. In addition, an interaction term of private provider times directly observed therapy was also significantly associated with mortality.

Conclusions

We identified factors independently associated with increased all-cause mortality following a diagnosis of tuberculosis. The associations between mortality and provider type should be evaluated with more thorough adjustment for severity of illness, but suggest important directions for future research.
Appendix
Available only for authorised users
Literature
1.
go back to reference Global Tuberculosis Programme: Global tuberculosis control: WHO report. 2009, Geneva: Global Tuberculosis Programme World Health Organization, vol. Began with 1997 Global Tuberculosis Programme: Global tuberculosis control: WHO report. 2009, Geneva: Global Tuberculosis Programme World Health Organization, vol. Began with 1997
2.
go back to reference Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC: Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA. 1999, 282 (7): 677-686. 10.1001/jama.282.7.677.CrossRefPubMed Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC: Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA. 1999, 282 (7): 677-686. 10.1001/jama.282.7.677.CrossRefPubMed
3.
go back to reference Fielder JF, Chaulk CP, Dalvi M, Gachuhi R, Comstock GW, Sterling TR: A high tuberculosis case-fatality rate in a setting of effective tuberculosis control: implications for acceptable treatment success rates. Int J Tuberc Lung Dis. 2002, 6 (12): 1114-1117.PubMed Fielder JF, Chaulk CP, Dalvi M, Gachuhi R, Comstock GW, Sterling TR: A high tuberculosis case-fatality rate in a setting of effective tuberculosis control: implications for acceptable treatment success rates. Int J Tuberc Lung Dis. 2002, 6 (12): 1114-1117.PubMed
4.
go back to reference Chiang CY, Enarson DA, Yu MC, Bai KJ, Huang RM, Hsu CJ, Suo J, Lin TP: Outcome of pulmonary multidrug-resistant tuberculosis: a 6-yr follow-up study. Eur Respir J. 2006, 28 (5): 980-985. 10.1183/09031936.06.00125705.CrossRefPubMed Chiang CY, Enarson DA, Yu MC, Bai KJ, Huang RM, Hsu CJ, Suo J, Lin TP: Outcome of pulmonary multidrug-resistant tuberculosis: a 6-yr follow-up study. Eur Respir J. 2006, 28 (5): 980-985. 10.1183/09031936.06.00125705.CrossRefPubMed
5.
go back to reference Chan ED, Laurel V, Strand MJ, Chan JF, Huynh ML, Goble M, Iseman MD: Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2004, 169 (10): 1103-1109. 10.1164/rccm.200308-1159OC.CrossRefPubMed Chan ED, Laurel V, Strand MJ, Chan JF, Huynh ML, Goble M, Iseman MD: Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2004, 169 (10): 1103-1109. 10.1164/rccm.200308-1159OC.CrossRefPubMed
6.
go back to reference van der Sande MA, Schim van der Loeff MF, Bennett RC, Dowling M, Aveika AA, Togun TO, Sabally S, Jeffries D, Adegbola RA, Sarge-Njie R, et al: Incidence of tuberculosis and survival after its diagnosis in patients infected with HIV-1 and HIV-2. AIDS. 2004, 18 (14): 1933-1941. 10.1097/00002030-200409240-00009.CrossRefPubMed van der Sande MA, Schim van der Loeff MF, Bennett RC, Dowling M, Aveika AA, Togun TO, Sabally S, Jeffries D, Adegbola RA, Sarge-Njie R, et al: Incidence of tuberculosis and survival after its diagnosis in patients infected with HIV-1 and HIV-2. AIDS. 2004, 18 (14): 1933-1941. 10.1097/00002030-200409240-00009.CrossRefPubMed
7.
go back to reference Pablos-Mendez A, Sterling TR, Frieden TR: The relationship between delayed or incomplete treatment and all-cause mortality in patients with tuberculosis. JAMA. 1996, 276 (15): 1223-1228. 10.1001/jama.276.15.1223.CrossRefPubMed Pablos-Mendez A, Sterling TR, Frieden TR: The relationship between delayed or incomplete treatment and all-cause mortality in patients with tuberculosis. JAMA. 1996, 276 (15): 1223-1228. 10.1001/jama.276.15.1223.CrossRefPubMed
8.
go back to reference Sterling TR, Zhao Z, Khan A, Chaisson RE, Schluger N, Mangura B, Weiner M, Vernon A: Mortality in a large tuberculosis treatment trial: modifiable and non-modifiable risk factors. Int J Tuberc Lung Dis. 2006, 10 (5): 542-549.PubMed Sterling TR, Zhao Z, Khan A, Chaisson RE, Schluger N, Mangura B, Weiner M, Vernon A: Mortality in a large tuberculosis treatment trial: modifiable and non-modifiable risk factors. Int J Tuberc Lung Dis. 2006, 10 (5): 542-549.PubMed
9.
go back to reference Anyama N, Bracebridge S, Black C, Niggebrugge A, Griffin SJ: What happens to people diagnosed with tuberculosis? A population-based cohort. Epidemiol Infect. 2007, 135 (7): 1069-1076. 10.1017/S0950268807007996.CrossRefPubMedPubMedCentral Anyama N, Bracebridge S, Black C, Niggebrugge A, Griffin SJ: What happens to people diagnosed with tuberculosis? A population-based cohort. Epidemiol Infect. 2007, 135 (7): 1069-1076. 10.1017/S0950268807007996.CrossRefPubMedPubMedCentral
10.
go back to reference Low S, Ang LW, Cutter J, James L, Chee CB, Wang YT, Chew SK: Mortality among tuberculosis patients on treatment in Singapore. Int J Tuberc Lung Dis. 2009, 13 (3): 328-334.PubMed Low S, Ang LW, Cutter J, James L, Chee CB, Wang YT, Chew SK: Mortality among tuberculosis patients on treatment in Singapore. Int J Tuberc Lung Dis. 2009, 13 (3): 328-334.PubMed
11.
go back to reference Khan K, Campbell A, Wallington T, Gardam M: The impact of physician training and experience on the survival of patients with active tuberculosis. CMAJ. 2006, 175 (7): 749-753.CrossRefPubMedPubMedCentral Khan K, Campbell A, Wallington T, Gardam M: The impact of physician training and experience on the survival of patients with active tuberculosis. CMAJ. 2006, 175 (7): 749-753.CrossRefPubMedPubMedCentral
13.
go back to reference Initial therapy for tuberculosis in the era of multidrug resistance. Recommendations of the Advisory Council for the Elimination of Tuberculosis. MMWR Recomm Rep. 1993, 42 (RR-7): 1-8. Initial therapy for tuberculosis in the era of multidrug resistance. Recommendations of the Advisory Council for the Elimination of Tuberculosis. MMWR Recomm Rep. 1993, 42 (RR-7): 1-8.
14.
go back to reference Horne DJ, Hubbard R, Narita M, Exarchos A, Goss CH: Survival following a diagnosis of tuberculosis in Washington State. Am J Respir Crit Care Med. 2009, 179: A5281- Horne DJ, Hubbard R, Narita M, Exarchos A, Goss CH: Survival following a diagnosis of tuberculosis in Washington State. Am J Respir Crit Care Med. 2009, 179: A5281-
15.
go back to reference Curtis AB ME, McKenna M, et al: Completeness and timeliness of tuberculosis case reporting, a multistate study. Am J Prev Med. 2001, 20: 108-112. 10.1016/S0749-3797(00)00284-1.CrossRefPubMed Curtis AB ME, McKenna M, et al: Completeness and timeliness of tuberculosis case reporting, a multistate study. Am J Prev Med. 2001, 20: 108-112. 10.1016/S0749-3797(00)00284-1.CrossRefPubMed
16.
go back to reference American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: controlling tuberculosis in the United States. Am J Respir Crit Care Med. 2005, 172 (9): 1169-1227. 10.1164/rccm.2508001. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: controlling tuberculosis in the United States. Am J Respir Crit Care Med. 2005, 172 (9): 1169-1227. 10.1164/rccm.2508001.
18.
go back to reference Driver CR, Munsiff SS, Li J, Kundamal N, Osahan SS: Relapse in persons treated for drug-susceptible tuberculosis in a population with high coinfection with human immunodeficiency virus in New York City. Clin Infect Dis. 2001, 33 (10): 1762-1769. 10.1086/323784.CrossRefPubMed Driver CR, Munsiff SS, Li J, Kundamal N, Osahan SS: Relapse in persons treated for drug-susceptible tuberculosis in a population with high coinfection with human immunodeficiency virus in New York City. Clin Infect Dis. 2001, 33 (10): 1762-1769. 10.1086/323784.CrossRefPubMed
19.
go back to reference Singh GK MB: Health, life expectancy, and mortality patterns among immigrant populations in the United States. Canadian J Pub Health. 2004, 95: I14-21. Singh GK MB: Health, life expectancy, and mortality patterns among immigrant populations in the United States. Canadian J Pub Health. 2004, 95: I14-21.
20.
go back to reference Weis SE, Slocum PC, Blais FX, King B, Nunn M, Matney GB, Gomez E, Foresman BH: The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med. 1994, 330 (17): 1179-1184. 10.1056/NEJM199404283301702.CrossRefPubMed Weis SE, Slocum PC, Blais FX, King B, Nunn M, Matney GB, Gomez E, Foresman BH: The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med. 1994, 330 (17): 1179-1184. 10.1056/NEJM199404283301702.CrossRefPubMed
21.
go back to reference Jasmer RM, Seaman CB, Gonzalez LC, Kawamura LM, Osmond DH, Daley CL: Tuberculosis treatment outcomes: directly observed therapy compared with self-administered therapy. Am J Respir Crit Care Med. 2004, 170 (5): 561-566. 10.1164/rccm.200401-095OC.CrossRefPubMed Jasmer RM, Seaman CB, Gonzalez LC, Kawamura LM, Osmond DH, Daley CL: Tuberculosis treatment outcomes: directly observed therapy compared with self-administered therapy. Am J Respir Crit Care Med. 2004, 170 (5): 561-566. 10.1164/rccm.200401-095OC.CrossRefPubMed
22.
go back to reference Kamolratanakul P, Sawert H, Lertmaharit S, Kasetjaroen Y, Akksilp S, Tulaporn C, Punnachest K, Na-Songkhla S, Payanandana V: Randomized controlled trial of directly observed treatment (DOT) for patients with pulmonary tuberculosis in Thailand. Transactions of the Royal Society of Tropical Medicine and Hygiene. 1999, 93 (5): 552-557. 10.1016/S0035-9203(99)90379-6.CrossRefPubMed Kamolratanakul P, Sawert H, Lertmaharit S, Kasetjaroen Y, Akksilp S, Tulaporn C, Punnachest K, Na-Songkhla S, Payanandana V: Randomized controlled trial of directly observed treatment (DOT) for patients with pulmonary tuberculosis in Thailand. Transactions of the Royal Society of Tropical Medicine and Hygiene. 1999, 93 (5): 552-557. 10.1016/S0035-9203(99)90379-6.CrossRefPubMed
23.
go back to reference Cayla JA, Rodrigo T, Ruiz-Manzano J, Caminero JA, Vidal R, Garcia JM, Blanquer R, Casals M: Tuberculosis treatment adherence and fatality in Spain. Respir Res. 2009, 10: 121-10.1186/1465-9921-10-121.CrossRefPubMedPubMedCentral Cayla JA, Rodrigo T, Ruiz-Manzano J, Caminero JA, Vidal R, Garcia JM, Blanquer R, Casals M: Tuberculosis treatment adherence and fatality in Spain. Respir Res. 2009, 10: 121-10.1186/1465-9921-10-121.CrossRefPubMedPubMedCentral
24.
go back to reference Coady SA, Sorlie PD, Cooper LS, Folsom AR, Rosamond WD, Conwill DE: Validation of death certificate diagnosis for coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. J Clin Epidemiol. 2001, 54 (1): 40-50. 10.1016/S0895-4356(00)00272-9.CrossRefPubMed Coady SA, Sorlie PD, Cooper LS, Folsom AR, Rosamond WD, Conwill DE: Validation of death certificate diagnosis for coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. J Clin Epidemiol. 2001, 54 (1): 40-50. 10.1016/S0895-4356(00)00272-9.CrossRefPubMed
Metadata
Title
Factors associated with mortality in patients with tuberculosis
Authors
David J Horne
Rebecca Hubbard
Masahiro Narita
Alexia Exarchos
David R Park
Christopher H Goss
Publication date
01-12-2010
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2010
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/1471-2334-10-258

Other articles of this Issue 1/2010

BMC Infectious Diseases 1/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.